Autolus Therapeutics (AUTL) Price & Analysis

Compare

689 Followers

AUTL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $5.00

Previous CloseN/A

Volume359.61K

Average Volume (3M)1.56M

Market Cap

$630.76M

Enterprise Value$205.61M

Total Cash (Recent Filing)$516.58M

Total Debt (Recent Filing)$57.71M

Price to Earnings (P/E)―

Beta1.91

Next Earnings

Aug 12, 2025

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding266,141,420

10 Day Avg. Volume1,910,209

30 Day Avg. Volume1,561,925

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue22.82

Enterprise Value/Gross Profit-8.38

Enterprise Value/Ebitda-0.87

Forecast

1Y Price Target

$10.00

Price Target Upside320.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Market ExpansionStrong growth in 2025 is expected as the company aims to expand to 60 target centers, covering about 90% of the target population.

Product EfficacyStrong efficacy/safety data demonstrated in the pivotal FELIX study contributed to the positive regulatory decision for Aucatzyl.

Regulatory ApprovalsAucatzyl received conditional EU approval in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Sales PerformanceAutolus reported an impressive $9.0 million in sales for Aucatzyl in the first quarter, substantially beating the estimate of $2.9 million.

Bears Say

Market CoverageThe launch of Aucatzyl with only about 60% of the target U.S. B-ALL population covered by activated centers is considered a strong start.

Regulatory ChallengesReceiving a positive NICE opinion will be important for achieving widespread payor coverage.

Autolus Therapeutics News

Autolus announces EC granted marketing authorization for AUCATZYL

Autolus Therapeutics (AUTL) announces that the European Commission, EC, has granted marketing authorization for AUCATZYL for the treatment...

18d ago

AUTL

Positive Outlook for Autolus Therapeutics Amid EU Approval and Strong Sales Performance

Autolus Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from...

18d ago

AUTL

Autolus Therapeutics Passes All AGM Resolutions

An announcement from Autolus Therapeutics ( ($AUTL) ) is now available. On June 26, 2025, Autolus Therapeutics held...

1M ago

AUTL

Promising FELIX Study Results for Obe-cel Support Buy Rating Amidst Strong Remission and Survival Rates

Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) and keeping...

2M ago

AUTL

Autolus Therapeutics Releases UK Annual Report 2024

Autolus Therapeutics ( ($AUTL) ) has shared an announcement. On June 2, 2025, Autolus Therapeutics plc released its...

2M ago

AUTL

Autolus Therapeutics Directors Announce Departure Plans

Autolus Therapeutics ( ($AUTL) ) has provided an announcement. On May 23, 2025, Drs. Joseph Anderson and Martin...

2M ago

AUTL

Autolus Therapeutics announces positive CHMP opinion for obe-cel

Autolus Therapeutics (AUTL) announces that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP,...

3M ago

AUTL

Autolus Therapeutics presents clinical data updates at EHA Congress

Autolus Therapeutics (AUTL) announces the online publication of three abstracts submitted to the European Hematology Association Congress, to...

3M ago

AUTL

Autolus Therapeutics’ Earnings Call: AUCATZYL’s Strong Start Amid Financial Challenges

Autolus Therapeutics (($AUTL)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

AUTL

Autolus Therapeutics Reports Q1 2025 Earnings and Progress

Autolus Therapeutics ( ($AUTL) ) has released its Q1 earnings. Here is a breakdown of the information Autolus...

3M ago

AUTL

Autolus Therapeutics files to sell 54.58M American depositary shares for holders

17:10 EDT Autolus Therapeutics (AUTL) files to sell 54.58M American depositary shares for holders Published first on TheFly...

3M ago

AUTL

Autolus Therapeutics: Strong Q1 Performance and Strategic Expansion Justify Buy Rating

Analyst Gil Blum of Needham reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report), retaining the...

3M ago

AUTL

Autolus Therapeutics Reports Q1 2025 Financial Results

Autolus Therapeutics ( ($AUTL) ) has issued an update. Autolus Therapeutics reported its financial results for the first...

3M ago

AUTL

Strong Market Entry and Strategic Expansion Drive Buy Rating for Autolus

William Blair analyst Matt Phipps has reiterated their bullish stance on AUTL stock, giving a Buy rating on...

3M ago

AUTL

AUTL FAQ

What was Autolus Therapeutics’s price range in the past 12 months?

Autolus Therapeutics lowest stock price was $1.10 and its highest was $5.00 in the past 12 months.

What is Autolus Therapeutics’s market cap?

Autolus Therapeutics’s market cap is $630.76M.

When is Autolus Therapeutics’s upcoming earnings report date?

Autolus Therapeutics’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.

How were Autolus Therapeutics’s earnings last quarter?

Autolus Therapeutics released its earnings results on May 08, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.243 by -$0.017.

Is Autolus Therapeutics overvalued?

According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Autolus Therapeutics pay dividends?

Autolus Therapeutics does not currently pay dividends.

What is Autolus Therapeutics’s EPS estimate?

Autolus Therapeutics’s EPS estimate is -0.23.

How many shares outstanding does Autolus Therapeutics have?

Autolus Therapeutics has 266,141,420 shares outstanding.

What happened to Autolus Therapeutics’s price movement after its last earnings report?

Autolus Therapeutics reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.243. Following the earnings report the stock price went up 9.756%.

Which hedge fund is a major shareholder of Autolus Therapeutics?

Currently, no hedge funds are holding shares in AUTL

Autolus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-49.91%

Trailing 12-Months

Asset Growth

-17.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Autolus Therapeutics

Autolus Therapeutics (AUTL) is a clinical-stage biopharmaceutical company focusing on the development of next-generation, programmed T cell therapies for the treatment of cancer. The company specializes in engineering T cells to recognize and attack cancer cells, leveraging its proprietary T cell programming technology. Autolus aims to offer innovative solutions in the field of oncology, targeting hematological malignancies and solid tumors.

Autolus Therapeutics (AUTL) Earnings & Revenues

Historic Earnings Reports

AUTL Company Deck

AUTL Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a strong start for AUCATZYL with significant interest and revenue generation. Geographic expansion and promising data in autoimmune diseases further bolstered positive outlooks. However, high costs and increased net loss present financial challenges that need addressing.View all AUTL earnings summaries

AUTL Stock 12 Month Forecast

Average Price Target

$10.00

▲(320.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.8830769230769233,3.476153846153846,4.069230769230769,4.662307692307692,5.2553846153846155,5.848461538461539,6.441538461538461,7.0346153846153845,7.627692307692308,8.220769230769232,8.813846153846153,9.406923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.8830769230769233,3.476153846153846,4.069230769230769,4.662307692307692,5.2553846153846155,5.848461538461539,6.441538461538461,7.0346153846153845,7.627692307692308,8.220769230769232,8.813846153846153,9.406923076923077,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.29,2.8830769230769233,3.476153846153846,4.069230769230769,4.662307692307692,5.2553846153846155,5.848461538461539,6.441538461538461,7.0346153846153845,7.627692307692308,8.220769230769232,8.813846153846153,9.406923076923077,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >